Safety Study of Kudiezi(Yueanxin,a Chinese Medicine Injection)Used in Hospitals in China
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01781676|
Recruitment Status : Unknown
Verified April 2013 by Yanming Xie, China Academy of Chinese Medical Sciences.
Recruitment status was: Active, not recruiting
First Posted : February 1, 2013
Last Update Posted : May 14, 2013
This study was advocated by institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences in October 2011.
It was funded by China major scientific and technological specialized specialized project for 'significant new formulation of net drugs'.
Kudiezi(Yueanxin) is kind of Chinese Medicine injiection used for treating corinary heart diswese、angina pectoris and stroke in many Chinese hospitals.
The purpose of this study is to determine adverse drug events or adverse drug reaction in large sample size 30,000 patients.
|Condition or disease|
|Coronary Heart Disease Angina Pectoris Stroke|
It is very common that Chinese Medicine Injection used in hospitals in mainland China.However safety problems rose in recent years.There could be many uncertain factors influence Chinese Medincine Injection in clinical practice.
Safety surveillance on Chinese Medincine injection is an important problem that needs to be sorted out through large sample observational dtudy.
A registry study for Kudiezi(Yueanxin) injection safety surveillance with 30000 patients will be conducted form Jan.2012 to Dec.2015.
Eligiblity crteria Patients who will use Kudiezi(Yueanxin) injection in selected hospitals.
Date will be collected in four aspects by four different forms as following:
Form A(blue):demographic information ;Form B(yellow):adverde drug events/reaction;Form C(white):extracted information from hodpiral information system and laboratory information system.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||30000 participants|
|Target Follow-Up Duration:||14 Days|
|Official Title:||Registry Study Intensive Hospital Monitoring Protocol of Kudiezi Injection ( Yueanxin ) 's Clinical Safety|
|Study Start Date :||January 2012|
|Estimated Primary Completion Date :||December 2014|
|Estimated Study Completion Date :||December 2015|
- Number of participants with adverse events;incidence of Kudiezi(Yueanxin)'ADRs and identify factors that contributed to the occurrence of the adverse reaction [ Time Frame: to assess Kudiezi(Yueanxin)'s 'adverse event' and 'drug adverse reaction' during patients' hospital stay,administration information of Kudiezi will be registered every day.The registry procedure will last 3 years only for patients using Kudiezi. ]All patients will be measured and assessed at the time Kudiezi(Yueanxin) is adminnistered to them until they discharge.Patients using Kudiezi(Yueanxin) will be registered on a regisration form including disease background, Kudiezi(Yueanxin)'s adminidtration,and extraction information from hospital information system.An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients.A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Kudiezi(Yueanxin).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01781676
|Institute of Basic Research in Clinical Medicine|
|Beijing, Beijing, China, 100700|
|Principal Investigator:||Xie Y Ming, BA||China Academy of Chinese Medical Sciences|